Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
MDXG's Cash to Debt is ranked higher than
99% of the 393 Companies
in the Global Medical Devices industry.

( Industry Median: 1.80 vs. MDXG: No Debt )
MDXG' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: No Debt

Equity to Asset 0.87
MDXG's Equity to Asset is ranked higher than
92% of the 373 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. MDXG: 0.87 )
MDXG' s 10-Year Equity to Asset Range
Min: 0.44   Max: 0.89
Current: 0.87

0.44
0.89
F-Score: 5
Z-Score: 38.52
M-Score: -2.08
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -3.72
MDXG's Operating margin (%) is ranked higher than
60% of the 383 Companies
in the Global Medical Devices industry.

( Industry Median: 6.29 vs. MDXG: -3.72 )
MDXG' s 10-Year Operating margin (%) Range
Min: -1334.98   Max: -4.46
Current: -3.72

-1334.98
-4.46
Net-margin (%) -3.84
MDXG's Net-margin (%) is ranked higher than
60% of the 383 Companies
in the Global Medical Devices industry.

( Industry Median: 5.11 vs. MDXG: -3.84 )
MDXG' s 10-Year Net-margin (%) Range
Min: -1447.4   Max: -6.95
Current: -3.84

-1447.4
-6.95
ROE (%) -5.20
MDXG's ROE (%) is ranked higher than
60% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 5.84 vs. MDXG: -5.20 )
MDXG' s 10-Year ROE (%) Range
Min: -376.59   Max: -8.79
Current: -5.2

-376.59
-8.79
ROA (%) -4.43
MDXG's ROA (%) is ranked higher than
60% of the 393 Companies
in the Global Medical Devices industry.

( Industry Median: 3.49 vs. MDXG: -4.43 )
MDXG' s 10-Year ROA (%) Range
Min: -557.14   Max: -6.86
Current: -4.43

-557.14
-6.86
ROC (Joel Greenblatt) (%) -17.04
MDXG's ROC (Joel Greenblatt) (%) is ranked higher than
59% of the 392 Companies
in the Global Medical Devices industry.

( Industry Median: 12.42 vs. MDXG: -17.04 )
MDXG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2782.83   Max: -22.82
Current: -17.04

-2782.83
-22.82
Revenue Growth (%) 293.60
MDXG's Revenue Growth (%) is ranked higher than
100% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. MDXG: 293.60 )
MDXG' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 293.6
Current: 293.6

0
293.6
EBITDA Growth (%) -50.00
MDXG's EBITDA Growth (%) is ranked higher than
50% of the 278 Companies
in the Global Medical Devices industry.

( Industry Median: -2.40 vs. MDXG: -50.00 )
MDXG' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 81.7
Current: -50

0
81.7
EPS Growth (%) -40.50
MDXG's EPS Growth (%) is ranked higher than
52% of the 268 Companies
in the Global Medical Devices industry.

( Industry Median: 1.00 vs. MDXG: -40.50 )
MDXG' s 10-Year EPS Growth (%) Range
Min: -40.5   Max: 260
Current: -40.5

-40.5
260
» MDXG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

MDXG Guru Trades in

Q4 2013

MDXG Guru Trades in Q4 2013

Steven Cohen 898,000 sh (New)
Jim Simons 100,350 sh (New)
Caxton Associates 50,000 sh (New)
» More
Q1 2014

MDXG Guru Trades in Q1 2014

Steven Cohen 1,035,000 sh (+15.26%)
Caxton Associates Sold Out
Jim Simons Sold Out
» More
Q2 2014

MDXG Guru Trades in Q2 2014

Jim Simons 179,900 sh (New)
Steven Cohen 906,800 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with MDXG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 10.00
MDXG's P/B is ranked higher than
50% of the 416 Companies
in the Global Medical Devices industry.

( Industry Median: 3.41 vs. MDXG: 10.00 )
MDXG' s 10-Year P/B Range
Min: 5.5   Max: 21.82
Current: 10

5.5
21.82
P/S 8.70
MDXG's P/S is ranked higher than
56% of the 416 Companies
in the Global Medical Devices industry.

( Industry Median: 3.07 vs. MDXG: 8.70 )
MDXG' s 10-Year P/S Range
Min: 6.84   Max: 148
Current: 8.7

6.84
148
EV-to-EBIT -243.48
MDXG's EV-to-EBIT is ranked higher than
57% of the 416 Companies
in the Global Medical Devices industry.

( Industry Median: 37.22 vs. MDXG: -243.48 )
MDXG' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -243.48

Current Ratio 6.69
MDXG's Current Ratio is ranked higher than
92% of the 391 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. MDXG: 6.69 )
MDXG' s 10-Year Current Ratio Range
Min: 0.05   Max: 7.08
Current: 6.69

0.05
7.08
Quick Ratio 6.26
MDXG's Quick Ratio is ranked higher than
93% of the 391 Companies
in the Global Medical Devices industry.

( Industry Median: 2.07 vs. MDXG: 6.26 )
MDXG' s 10-Year Quick Ratio Range
Min: 0.05   Max: 6.7
Current: 6.26

0.05
6.7

Valuation & Return

vs
industry
vs
history
Price/Net Cash 27.50
MDXG's Price/Net Cash is ranked higher than
87% of the 416 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. MDXG: 27.50 )
MDXG' s 10-Year Price/Net Cash Range
Min: 20.43   Max: 140
Current: 27.5

20.43
140
Price/Net Current Asset Value 16.63
MDXG's Price/Net Current Asset Value is ranked higher than
81% of the 416 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. MDXG: 16.63 )
MDXG' s 10-Year Price/Net Current Asset Value Range
Min: 13.62   Max: 140
Current: 16.63

13.62
140
Price/Tangible Book 12.77
MDXG's Price/Tangible Book is ranked higher than
56% of the 416 Companies
in the Global Medical Devices industry.

( Industry Median: 5.89 vs. MDXG: 12.77 )
MDXG' s 10-Year Price/Tangible Book Range
Min: 10.57   Max: 237.5
Current: 12.77

10.57
237.5
Price/Median PS Value 0.73
MDXG's Price/Median PS Value is ranked higher than
89% of the 416 Companies
in the Global Medical Devices industry.

( Industry Median: 1.15 vs. MDXG: 0.73 )
MDXG' s 10-Year Price/Median PS Value Range
Min: 0.58   Max: 9.64
Current: 0.73

0.58
9.64
Forward Rate of Return (Yacktman) -4.38
MDXG's Forward Rate of Return (Yacktman) is ranked higher than
65% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 1.34 vs. MDXG: -4.38 )
MDXG' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 9.5   Max: 9.8
Current: -4.38

9.5
9.8

Business Description

Industry: Medical Devices » Medical Devices
Compare: » details
Traded in other countries:MXE.Germany
MiMedx Group, Inc., was incorporated in Florida on February 28, 2008. It is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and allografts processed from human amniotic membrane. Its biomaterial platform technologies include the device technologies HydroFix and CollaFixM, and its tissue technologies, AmnioFix and EpiFix. It is a supplier of allografts processed from amniotic tissue, having supplied over 120,000 allografts to date for application in the Surgical, Orthopedic, Spinal, Wound Care, Ophthalmic, and Dental segments of healthcare. The first clinical uses of fresh amnion were for wound care patients and burn victims. Its technology and products are AmnioFix, EpiFix and other Tissue -Based Allografts and Medical Devices- CollaFix and HydroFix. There have been over 150 publications on the use of amniotic membrane for uses from wound care to gingival recession and from pterygium repair to the reduction of fibrous tissue following spinal surgery. The amniotic membrane has been shown to reduce inflammation, down regulate scar tissue and promote the regeneration of soft tissues. The Company operates a licensed tissue bank. The Company is a regenerative biomaterials company with three platform technologies. Its addressable market is in chronic wound care consisting of diabetic, venous and pressure ulcers. The Orthopedic, General Surgery, Urology and OB/GYN soft tissue repair markets also represent market opportunities. In 2012, the Company established a direct sales force for Government accounts and is developing a direct sales force for commercial wound care.
» More Articles for MDXG

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
MiMedx to Present at the Stem Cell Meeting on the Mesa Sep 30 2014
Study Determines MiMedx Allograft Effectively Recruits Circulating Stem and Progenitor Cells Sep 24 2014
MiMedx Signs Distribution Agreement With Zimmer Sep 18 2014
MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal Sep 17 2014
MiMedx To Webcast Its Analyst Day On October 14th Sep 08 2014
Fifth MiMedx Scientific Study Published In Peer-Reviewed Journal Sep 03 2014
MIMEDX GROUP, INC. Financials Aug 19 2014
MIMEDX GROUP, INC. Files SEC form 10-Q, Quarterly Report Aug 11 2014
MiMedx To Present At 34th Annual Canaccord|Genuity Growth Conference Aug 04 2014
MIMEDX GROUP, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of... Jul 31 2014
MiMedx Group Inc Earnings Call scheduled for 10:30 am ET today Jul 29 2014
MIMEDX GROUP, INC. Files SEC form 8-K/A, Results of Operations and Financial Condition, Financial... Jul 29 2014
Q2 2014 MiMedx Group Inc Earnings Release - After Market Close Jul 29 2014
/C O R R E C T I O N -- MiMedx Group, Inc./ Jul 28 2014
MIMEDX GROUP, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jul 28 2014
MiMedx Files Its Initial Investigational New Drug Application Jul 23 2014
Restrospective Analysis Finds MiMedx EpiFix® As Most Effective In Rapid Resolution Of Diabetic Foot... Jul 22 2014
MiMedx Announces Release Date For 2014 Second Quarter Results Jul 15 2014
Coverage initiated on MiMedx Group by Needham Jul 15 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK